Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
Benjamin Levy, Enriqueta Felip, Martin Reck, et al.
Future Oncology (2023) Vol. 19, Iss. 21, pp. 1461-1472
Open Access | Times Cited: 19

Showing 19 citing articles:

Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
Hirokazu Suzuki, Shotaro Nagase, C. Saito, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 3, pp. 257-271
Open Access | Times Cited: 11
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
Solange Peters, Sherene Loi, Fabrice André, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 607-629
Closed Access | Times Cited: 9
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Darin Poei, Sana Ali, Shirley Ye, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 9
A bioactive polysaccharide derived from Rosa laevigata fruits: Structural properties, antitumor efficacy, and potential mechanisms
Xiaoyang Guo, Fan Nie, Haojing Jiang, et al.
International Journal of Biological Macromolecules (2025), pp. 140382-140382
Closed Access | Times Cited: 1
Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives
Shuangsi Liao, Xiaoling Li, You Lü, et al.
Small Methods (2025)
Open Access | Times Cited: 1
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Lijun Li, Haihong Pu, Xiaoxin Zhang, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 209, pp. 104683-104683
Closed Access | Times Cited: 1
The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
Xinlin Liu, Junwen Deng, Renshuai Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Unlocking the therapeutic potential of antibody–drug conjugates in targeting molecular biomarkers in non-small cell lung cancer
Shruti Soni, Kaivalya Megha, Vraj B. Shah, et al.
Journal of the Egyptian National Cancer Institute (2025) Vol. 37, Iss. 1
Open Access
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls
Gianluca Russo, Claudia Scimone, Lucia Palumbo, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104748-104748
Open Access
Datopotamab Deruxtecan: First Approval
Hannah A. Blair
Drugs (2025)
Closed Access
Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer
Jong Chul Park, Donghoon Shin
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 3
Cancer Stem Cell Metastatic Checkpoints and Glycosylation Patterns: Implications for Therapeutic Strategies
Sara Sadat Aghamiri, Rada Amin
Kinases and Phosphatases (2024) Vol. 2, Iss. 2, pp. 151-165
Open Access | Times Cited: 2
Antibody–Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives
Carol Zanchetta, Lorenzo De Marchi, Marianna Macerelli, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 221-221
Open Access | Times Cited: 2
Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC
Xiehui Chen, Changchun Zeng
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 4, pp. 556-584
Closed Access | Times Cited: 1
Immunohistochemistry of Lung Cancer Biomarkers
Mary Beth Beasley
Advances in Anatomic Pathology (2024) Vol. 31, Iss. 5, pp. 333-343
Closed Access | Times Cited: 1
Antibody-drug conjugates in solid tumors: a new frontier
Salvador Jaime-Casas, Regina Barragán-Carrillo, Abhishek Tripathi
Current Opinion in Oncology (2024) Vol. 36, Iss. 5, pp. 421-429
Closed Access | Times Cited: 1
Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery
Hyein Jeon, Rajvi Gor, Angelica D’Aiello, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access
What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review
Alberto Giuseppe Agostara, Laura Roazzi, Federica Villa, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 9, pp. 787-803
Closed Access | Times Cited: 1
Advancements in non-small cell lung cancer treatment: from early to advanced stages
Adam Płużański, Aleksandra Piórek
Oncology in Clinical Practice (2024)
Open Access
Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases
David J. H. Bian, Sara Frida Cohen, Anna-Maria Lazaratos, et al.
Current Oncology (2024) Vol. 31, Iss. 10, pp. 6314-6342
Open Access
Page 1

Scroll to top